Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17103783 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE | November 2020 | June 2024 | Abandon | 43 | 1 | 0 | Yes | No |
| 17095982 | Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy | November 2020 | March 2024 | Allow | 40 | 0 | 1 | No | No |
| 17094522 | METHOD OF SEPARATING VIRAL VECTORS | November 2020 | August 2023 | Allow | 33 | 2 | 0 | Yes | No |
| 17091549 | REPLICATION-ENHANCED ONCOLYTIC ADENOVIRUSES | November 2020 | February 2024 | Allow | 39 | 2 | 0 | No | No |
| 17072490 | CAL-T CONSTRUCTS AND USES THEREOF | October 2020 | March 2023 | Allow | 29 | 5 | 1 | Yes | No |
| 17042848 | LIPID PARTICLES FOR NUCLEIC ACID DELIVERY | September 2020 | May 2024 | Allow | 43 | 1 | 0 | Yes | No |
| 16979049 | LIQUID COMPOSITION CONTAINING HIGH CONCENTRATION OF DNA FRAGMENT MIXTURE AND HAVING FLUIDITY AND PREPARATION METHOD THEREFOR | September 2020 | June 2024 | Abandon | 45 | 1 | 0 | No | No |
| 16976052 | DECELLULARIZED BONE BIOMATERIAL ENRICHED WITH A HYDROGEL CONTAINING DECELLULARIZED EXTRACELLULAR BONE MATRIX | August 2020 | January 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17002788 | METHODS FOR SCREENING VARIANT OF TARGET GENE | August 2020 | July 2022 | Allow | 22 | 4 | 1 | Yes | No |
| 16986798 | REPROGRAMMING OF NON-NEURONAL CELLS INTO NEURONS AND METHODS AND COMPOSITIONS TO TREAT NEURODEGENERATIVE DISEASES AND DISORDERS | August 2020 | March 2023 | Allow | 31 | 5 | 0 | Yes | No |
| 16967377 | CHIMERIC RECEPTOR | August 2020 | March 2024 | Abandon | 44 | 0 | 1 | No | No |
| 16940080 | RNA-Guided Targeting of Genetic and Epigenomic Regulatory Proteins to Specific Genomic Loci | July 2020 | January 2024 | Abandon | 42 | 1 | 1 | Yes | No |
| 16925039 | NOVEL GENETICALLY ENGINEERED VACCINIA VIRUSES | July 2020 | October 2023 | Abandon | 39 | 1 | 0 | No | No |
| 16909928 | ENGINEERED CELLS FOR ADOPTIVE CELL THERAPY | June 2020 | August 2023 | Abandon | 38 | 0 | 1 | No | No |
| 16907713 | Compositions and Methods for Treating Cancer with DuoCARs | June 2020 | June 2023 | Allow | 36 | 1 | 0 | Yes | No |
| 16849301 | Simian Adenovirus and Hybrid Adenoviral Vectors | April 2020 | August 2023 | Allow | 40 | 1 | 1 | No | No |
| 16754659 | Modified EC7 Cells Having Low Toxicity to Viral Production Payloads | April 2020 | June 2022 | Allow | 27 | 4 | 1 | Yes | No |
| 16842489 | NON-TRANSGENE TRANSFECTION FOR THERAPEUTIC PURPOSES | April 2020 | October 2023 | Allow | 42 | 4 | 0 | Yes | Yes |
| 16842440 | NON-DISRUPTIVE GENE TARGETING | April 2020 | June 2023 | Abandon | 39 | 0 | 1 | No | No |
| 16753016 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | April 2020 | June 2023 | Allow | 38 | 1 | 0 | No | No |
| 16824008 | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR PAH GENE TRANSFER AND METHODS OF USE THEREOF | March 2020 | January 2024 | Allow | 46 | 3 | 0 | No | No |
| 16798890 | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR PAH GENE TRANSFER AND METHODS OF USE THEREOF | February 2020 | April 2024 | Allow | 49 | 4 | 0 | Yes | No |
| 16796851 | Inducible Production-Phase Promoters for Coordinated Heterologous Expression in Yeast | February 2020 | June 2023 | Allow | 39 | 2 | 0 | Yes | No |
| 16778996 | GENOMIC INSULATOR ELEMENTS AND USES THEREOF | January 2020 | June 2023 | Allow | 40 | 2 | 0 | No | No |
| 16776850 | ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR | January 2020 | September 2023 | Abandon | 43 | 2 | 0 | No | No |
| 16773379 | Compositions and Methods For Treating Cancer With Anti-CD22 Immunotherapy | January 2020 | September 2023 | Allow | 44 | 3 | 0 | Yes | No |
| 16738015 | VECTORS CONDITIONALLY EXPRESSING THERAPEUTIC PROTEINS, HOST CELLS COMPRISING THE VECTORS, AND USES THEREOF | January 2020 | March 2023 | Abandon | 38 | 0 | 1 | No | No |
| 16730705 | CANCER IMAGING WITH THERAPY: THERANOSTICS | December 2019 | February 2023 | Abandon | 37 | 1 | 0 | No | No |
| 16717420 | LENTIVIRAL VECTOR FOR TREATING HEMOGLOBIN DISORDERS | December 2019 | July 2023 | Allow | 43 | 2 | 0 | Yes | No |
| 16620188 | PROMOTERS FROM CORYNEBACTERIUM GLUTAMICUM AND USES THEREOF IN REGULATING ANCILLARY GENE EXPRESSION | December 2019 | May 2024 | Abandon | 53 | 4 | 1 | No | No |
| 16702437 | GENETICALLY MODIFIED BACTERIA AND METHODS FOR GENETIC MODIFICATION OF BACTERIA | December 2019 | April 2024 | Allow | 53 | 4 | 0 | Yes | No |
| 16684028 | RNAi induced reduction of ataxin-3 for the treatment of Spinocerebellar ataxia type 3 | November 2019 | March 2023 | Abandon | 40 | 1 | 0 | No | No |
| 16675841 | ADENO-ASSOCIATED VIRUS FACTOR VIII VECTORS, ASSOCIATED VIRAL PARTICLES AND THERAPEUTIC FORMULATIONS COMPRISING THE SAME | November 2019 | February 2023 | Allow | 39 | 1 | 0 | No | No |
| 16667608 | Simian Adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50, and Uses Thereof | October 2019 | August 2023 | Allow | 46 | 1 | 1 | No | No |
| 16607653 | Cancer Treatment | October 2019 | June 2023 | Allow | 44 | 1 | 1 | No | No |
| 16658293 | TRANSIENT TRANSFECTION METHOD FOR RETROVIRAL PRODUCTION | October 2019 | February 2023 | Abandon | 40 | 1 | 0 | No | No |
| 16599473 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD19/CD20 IMMUNOTHERAPY | October 2019 | February 2023 | Allow | 40 | 1 | 0 | Yes | No |
| 16497277 | MeCP2 EXPRESSION CASSETTES | September 2019 | August 2023 | Allow | 46 | 1 | 1 | No | No |
| 16470520 | Programmable Oncolytic Virus Vaccine System and Method | September 2019 | May 2024 | Abandon | 59 | 4 | 0 | Yes | No |
| 16496110 | CELL CULTURE METHODS INVOLVING HDAC INHIBITORS OR REP PROTEINS | September 2019 | September 2023 | Allow | 48 | 3 | 0 | Yes | No |
| 16495974 | METHODS FOR ENHANCING YIELD OF RECOMBINANT ADENO-ASSOCIATED VIRUS | September 2019 | April 2023 | Abandon | 43 | 2 | 0 | No | No |
| 16573389 | TARGETING BCL11A DISTAL REGULATORY ELEMENTS FOR FETAL HEMOGLOBIN REINDUCTION | September 2019 | August 2022 | Allow | 35 | 2 | 1 | No | No |
| 16569742 | Adenoviral Polypeptide IX Increases Adenoviral Gene Therapy Vector Productivity and Infectivity | September 2019 | December 2022 | Abandon | 40 | 0 | 1 | No | No |
| 16489187 | PACS1 ENHANCEMENT FOR REV-DEPENDENT LENTIVIRAL VECTORS | August 2019 | January 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16488689 | MODIFIED AAV CAPSIDS AND USES THEREOF | August 2019 | November 2022 | Abandon | 39 | 1 | 1 | Yes | No |
| 16534280 | METHOD FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE II | August 2019 | May 2024 | Abandon | 58 | 4 | 1 | Yes | No |
| 16482055 | MULTIPLE TRANSGENE RECOMBINANT ADENOVIRUS | July 2019 | November 2022 | Abandon | 40 | 1 | 1 | No | No |
| 16481430 | RECOMBINANT VIRUS VECTORS FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE | July 2019 | May 2023 | Abandon | 46 | 2 | 1 | Yes | No |
| 16519889 | METHODS TO ENHANCE MYOCARDIAL REGENERATION AND/OR REPAIR | July 2019 | February 2023 | Allow | 43 | 2 | 0 | Yes | No |
| 16476960 | AAV Vector for Disrupting Coagulation Factor-Related Gene on Liver Genome | July 2019 | March 2024 | Abandon | 56 | 1 | 0 | No | No |
| 16458892 | Engineered Cellular Pathways for Programmed Autoregulation of Differentiation | July 2019 | January 2023 | Abandon | 42 | 4 | 0 | Yes | No |
| 16455745 | METHOD, SYSTEM AND RECOMBINANT BACMID FOR PREPARATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS | June 2019 | February 2023 | Allow | 44 | 3 | 0 | No | No |
| 16474312 | ONCOLYTIC VIRUSES AND THERAPEUTIC MOLECULES | June 2019 | February 2024 | Abandon | 56 | 4 | 1 | No | No |
| 16423215 | Adenoviral Polypeptide IX Increases Adenoviral Gene Therapy Vector Productivity and Infectivity | May 2019 | December 2022 | Abandon | 43 | 1 | 0 | No | No |
| 16411841 | STABLE EXPRESSION OF AAV VECTORS IN JUVENILE SUBJECTS | May 2019 | July 2024 | Abandon | 60 | 2 | 1 | No | No |
| 16407015 | METHODS OF TREATING PHENYLKETONURIA | May 2019 | April 2023 | Allow | 47 | 2 | 1 | Yes | No |
| 16383236 | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION | April 2019 | September 2021 | Allow | 29 | 2 | 0 | No | No |
| 16368042 | COMPOSITIONS AND METHODS FOR PROMOTING THE MINERALIZATION OF BIOLOGICAL TISSUE | March 2019 | January 2024 | Allow | 58 | 6 | 1 | Yes | No |
| 16299456 | RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INHIBITION OF EXPRESSION OF DUX4 | March 2019 | June 2023 | Allow | 51 | 5 | 0 | Yes | No |
| 16326131 | Retroviral And Lentiviral Vectors | February 2019 | December 2022 | Allow | 46 | 1 | 1 | Yes | No |
| 16317446 | COMPOSITIONS AND METHODS FOR IMPROVING IMMUNE SYSTEM FUNCTION | January 2019 | October 2022 | Allow | 45 | 1 | 2 | No | No |
| 16220048 | METHOD OF DIFFERENTIATING NEURAL STEM CELLS OR NEURAL PRECURSOR CELLS INTO DOPAMINE NEURONS | December 2018 | June 2023 | Abandon | 54 | 6 | 1 | Yes | No |
| 16099431 | Separation of Rare Cells and Genomic Analysis Thereof | November 2018 | June 2023 | Abandon | 56 | 4 | 0 | No | No |
| 16167764 | ENGINEERED VIRAL VECTOR REDUCES INDUCTION OF INFLAMMATORY AND IMMUNE RESPONSES | October 2018 | July 2023 | Abandon | 57 | 5 | 1 | Yes | Yes |
| 16092828 | SEQUENTIAL LOADINGS OF MULTIPLE DELIVERY VECTORS USING A SINGLE SELECTABLE MARKER | October 2018 | September 2023 | Allow | 59 | 3 | 1 | No | Yes |
| 16089992 | TRAIL-SECRETING MESENCHYMAL STEM CELLS AND USE THEREOF TO TREAT BRAIN TUMORS | September 2018 | November 2022 | Abandon | 50 | 0 | 1 | No | No |
| 16113908 | LARGE COMMERCIAL SCALE LENTIVIRAL VECTOR PRODUCTION SYSTEM AND VECTORS PRODUCED THEREBY | August 2018 | June 2023 | Allow | 58 | 4 | 0 | Yes | No |
| 16046939 | USE OF BACTERIAL VOLTAGE GATED ION CHANNELS FOR HUMAN THERAPIES | July 2018 | January 2024 | Allow | 60 | 5 | 0 | No | No |
| 16045619 | AAV VECTOR COMPOSITIONS AND METHODS FOR GENE TRANSFER TO CELLS, ORGANS AND TISSUES | July 2018 | November 2023 | Allow | 60 | 6 | 0 | Yes | Yes |
| 16011292 | METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF | June 2018 | February 2024 | Abandon | 60 | 6 | 1 | Yes | No |
| 16009975 | TARGETED DISRUPTION OF T CELL AND/OR HLA RECEPTORS | June 2018 | July 2022 | Allow | 49 | 3 | 1 | Yes | No |
| 16004871 | NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION | June 2018 | April 2024 | Abandon | 60 | 4 | 0 | No | No |
| 15997433 | INTRATHECAL DELIVERY OF RECOMBINANT ADENO-ASSOCIATED VIRUS 9 | June 2018 | July 2022 | Allow | 49 | 4 | 0 | Yes | No |
| 15911924 | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION | March 2018 | April 2022 | Allow | 50 | 3 | 1 | No | No |
| 15754227 | Methods and Compositions for Cells Expressing a Chimeric Intracellular Signaling Molecule | February 2018 | September 2023 | Allow | 60 | 4 | 1 | Yes | No |
| 15579633 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR IMPROVING TRANSPLANTATION | December 2017 | September 2023 | Allow | 60 | 7 | 1 | No | No |
| 15697655 | RECOMBINANT VIRUS PRODUCTION USING MAMMALIAN CELLS IN SUSPENSION | September 2017 | August 2024 | Abandon | 60 | 7 | 0 | No | No |
| 15542415 | METHOD FOR THE TREATMENT OF MALIGNANCIES | July 2017 | February 2023 | Abandon | 60 | 6 | 0 | Yes | No |
| 15535389 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF scAAV | June 2017 | February 2023 | Allow | 60 | 5 | 2 | No | No |
| 15615405 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | June 2017 | March 2023 | Abandon | 60 | 7 | 0 | Yes | No |
| 15533475 | COMPOSITIONS AND METHODS FOR EFFICIENT GENE EDITING IN E. COLI USING GUIDE RNA/CAS ENDONUCLEASE SYSTEMS IN COMBINATION WITH CIRCULAR POLYNUCLEOTIDE MODIFICATION TEMPLATES | June 2017 | February 2023 | Abandon | 60 | 7 | 0 | No | No |
| 15516240 | Altering Gene Expression in CART Cells and Uses Thereof | March 2017 | September 2023 | Abandon | 60 | 6 | 1 | Yes | No |
| 15476787 | COMPOSITIONS COMPRISING GRIM-19 THERAPEUTICS AND METHODS OF USE | March 2017 | September 2022 | Allow | 60 | 5 | 1 | No | No |
| 15449416 | GLOBIN GENE THERAPY FOR TREATING HEMOGLOBINOPATHIES | March 2017 | June 2022 | Allow | 60 | 5 | 1 | Yes | No |
| 15404890 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGIC DISEASE | January 2017 | November 2022 | Abandon | 60 | 6 | 1 | No | Yes |
| 15132190 | FRACTIONAL REGULATION OF TRANSCRIPTION | April 2016 | January 2023 | Allow | 60 | 8 | 1 | Yes | No |
| 14217070 | TREATMENT OF AUTOIMMUNE DISEASES | March 2014 | September 2022 | Allow | 60 | 9 | 0 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MARVICH, MARIA.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MARVICH, MARIA works in Art Unit 1631 and has examined 87 patent applications in our dataset. With an allowance rate of 55.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner MARVICH, MARIA's allowance rate of 55.2% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MARVICH, MARIA receive 2.98 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MARVICH, MARIA is 45 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +24.8% benefit to allowance rate for applications examined by MARVICH, MARIA. This interview benefit is in the 70% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 15.4% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 45.0% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 55.2% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.2% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.